Sudeep Pharma
Sudeep Pharma
HealthcareKey Fundamentals
MicrocapPharmaceuticalsHealthcarePrice-based figures as of 9 Oct 2026, 3:55 pm IST · EPS basis: Consolidated · TTM
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has delivered good profit growth of 39.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
Weaknesses
1- Stock is trading at 15.0 times its book value
Growth Rate
AI Analysis — Bull vs Bear
As of the 2026-10-05 close, Sudeep Pharma Ltd traded at ₹1,173.4, giving it a market capitalisation of ₹13,253.39 crore. At that price the stock was valued at 69.72x trailing earnings (EPS ₹16.83) and 15x book value. Its fundamentals are strong: 5-year profit CAGR of 39%, 3-year average ROE of 32%, ROCE of 24.22% and debt-to-equity of 0.17. Current ROE of 19.41% is well below its 3-year average, and 3-year sales growth of 14% is much slower than the 5-year rate of 24%.
- Profit has compounded at 39% CAGR over 5 years and 40% CAGR over 3 years. Over both periods, earnings grew much faster than sales (24% and 14% respectively), which points to operating leverage or a shift toward higher-margin products.
- Return ratios have been high. ROE averaged 32% over 3 and 5 years, and current ROCE is 24.22%, which suggests the business earns well on the capital it uses.
- The balance sheet carries little debt. Debt-to-equity is 0.17, which limits financial risk and leaves room to borrow for future capex or acquisitions.
- Growth has picked up again recently. TTM sales growth of 24% is well above the 3-year CAGR of 14%, and TTM profit growth is still 20%.
- 5-year sales CAGR of 24% shows demand has held up over a longer period, beyond any single strong year.
- The stock has shown strong momentum. At ₹1,173.4 on 2026-10-05, it was about 124% above its 52-week low of ₹524.05, which suggests the market has been warming to the story.
- The stock was about 14.8% below its 52-week high of ₹1,378. Part of the earlier peak valuation had already come off as of 2026-10-05.
- The valuation is demanding. A trailing P/E of 69.72x means an earnings yield of about 1.4%, so the price already assumes years of strong growth with little margin for error.
- At 15x book value, the stock prices in high return ratios for a long time. That gap looks harder to justify with current ROE at 19.41%.
- ROE has been falling. It was 32% on a 3-year basis, 25% last year and 19.41% currently, which could reflect a larger equity base, slower returns on new capital, or both.
- Sales growth slowed over the medium term. The 3-year CAGR of 14% is well below the 5-year CAGR of 24%, which suggests growth has not been steady.
- Profit is now growing slower than sales. TTM profit grew 20% against 24% sales growth, which may signal margin pressure after years of margin expansion.
- The 52-week range of ₹524.05 to ₹1,378 shows a high of about 2.6x the low. That means the stock has been very volatile, with a risk of sharp drawdowns if sentiment turns.
- Shareholder payouts are small. The dividend yield of 0.13% gives almost no income support at current prices, so returns depend almost entirely on growth.
- There is no multi-year stock return history (1, 3 and 5-year stock CAGR data are not available), so there is little public-market track record to judge how the stock behaves across cycles.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Nuvama CEO Forum participation Sep 23
Sudeep Pharma will take part in the Nuvama Emerging India CEO Forum 2026 in Mumbai on September 28, 2026. The company confirmed that no unpublished price sensitive information will be discussed.
- Gujarat plant visit investor meet Sep 16
Sudeep Pharma has scheduled analyst and institutional investor meetings in Gujarat on September 23-24, 2026, including plant visits.
TL;DR: The only recent news for Sudeep Pharma is routine investor outreach: plant visits in Gujarat on Sep 23-24 and the Nuvama Emerging India CEO Forum on Sep 28, 2026. These meetings show management is actively engaging institutional investors and may raise the stock's visibility, but they contain no financial or operational information that moves the fundamentals. No specific risks came up in this period, though the news flow is too thin to say whether the trend is improving or deteriorating. Watch for analyst commentary after the plant visits and the next quarterly results for clearer direction.
Quarterly Results
| Particulars | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| PBT | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS in Rs | 128 | 2.95 | 4.54 | 3.17 | 4.71 | 4.2 | 4.33 | 3.59 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Expenses | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 443 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 34% |
| Other Income | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 29 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| PBT | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | — |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS in Rs | 128 | 237 | 356 | 442 | 945 | 14.27 | 15.31 | 16.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 |
| Other Liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Fixed Assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Investing | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Financing | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | 0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/OP | 62 | 104 | 22 | 78 | 60 | 47 | 56 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | — | 36% | 36% | 33% | 49% | 36% | 28% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sudeep Pharma insights
64 extracted metrics + investor summaries across FY20–FY27.
Documents
Frequently Asked Questions about Sudeep Pharma
What does Sudeep Pharma Ltd do?
Where is Sudeep Pharma Ltd (SUDEEPPHRM) listed?
Which sector does Sudeep Pharma Ltd belong to?
What is the market capitalisation of Sudeep Pharma Ltd?
What is the PE ratio of Sudeep Pharma Ltd?
What is the 52-week high and low of Sudeep Pharma Ltd?
Does Sudeep Pharma Ltd pay dividends?
What is the Return on Equity (ROE) of Sudeep Pharma Ltd?
Company Information
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUDEEPPHRM.md for Sudeep Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.